Top Markets
#1 Helium Helium +51.12%
#2 TENDIES TENDIES +40.50%
#3 Pons Pons +28.45%
#4 Seeker Seeker +20.84%
#5 UnifAI Network UnifAI Network +19.25%
#6 Songbird Songbird +12.26%
#7 Lista DAO Lista DAO +11.34%
#8 OSK OSK +10.10%
#9 DAPPOS DAPPOS +9.96%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +9.71%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Rank in Stocks #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Share Price
$9.50
Last synced: 2025-01-08
Market Cap
$819.52M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Poseida Therapeutics, Inc. (PSTX)

Category

Healthcare
Number of shares outstanding for Poseida Therapeutics, Inc. (PSTX)
Number of shares outstanding as of September 2024: 97.16M
According to Poseida Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 97.16M. At the end of December 2022 the company had 71.91M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Poseida Therapeutics, Inc. (PSTX) from 2016 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 97.16M 7.73%
2023 90.19M 25.41%
2022 71.91M 15.66%
2021 62.18M 6.47%
2020 58.40M 46.98%
2019 39.73M 10.59%
2018 35.93M -9.57%
2017 39.73M -33.01%
2016 59.32M 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 161.32%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -36.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 392.91%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 307.57%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH